Tuesday’s Highlights at Noon: Microvision (MVIS), Cleveland-Cliffs (CLF), Karyopharm Therapeutics (KPTI), Snap (SNAP), Stem Inc (STEM)

By Carrie Williams

So far Tuesday, May 4, NASDAQ is down -0.81% and the S&P is down -2.23%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Microvision (MVISResearch Report), Cleveland-Cliffs (CLFResearch Report), Karyopharm Therapeutics (KPTIResearch Report), Snap (SNAPResearch Report) and Stem Inc (STEMResearch Report).

Microvision is up 20.33% in midday trading to $16.10. Shares opened today at $13.38. The company has a 52-week low of $0.55 and a 52-week high of $28.00.

Cleveland-Cliffs is up 8.95% in midday trading to $19.96. Shares opened today at $18.32. The company has a 52-week low of $3.80 and a 52-week high of $20.87. On the Street’s front, the average 12-month analyst price target for the stock is $25.40, marking a 38.65% potential upside from current levels. In a report released today, Credit Suisse analyst Curt Woodworth upgraded CLF to Buy, with a price target of $24.00, which represents a potential upside of 31% from where the stock is currently trading. Separately, on April 26, KeyBanc’s Philip Gibbs downgraded the stock to Hold . Over the last 3 months, the insider sentiment on Cleveland-Cliffs has been neutral based on 52 corporate insider transactions. This sentiment is slightly lower than the average sector sentiment of insiders.

Karyopharm Therapeutics is down -7.62% in midday trading to $8.55. Shares opened today at $9.25. The company has a 52-week low of $8.93 and a 52-week high of $21.82. On the Street’s front, the average 12-month analyst price target for the stock is $26.25, marking a 183.78% potential upside from current levels. In a report released today, Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on KPTI, with a price target of $30.00, which implies an upside of 224% from current levels. Over the last 3 months, the insider sentiment on Karyopharm Therapeutics has been negative based on 46 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Snap is down -7.23% in midday trading to $53.76. Shares opened today at $57.95. The company has a 52-week low of $16.42 and a 52-week high of $73.59. On the Street’s front, the average 12-month analyst price target for the stock is $79.36, marking a 36.95% potential upside from current levels. In a report released today, Citigroup analyst Jason Bazinet maintained a Sell rating on SNAP, with a price target of $47.00, which implies a downside of 19% from current levels. Separately, on April 23, Evercore ISI’s Mark Mahaney maintained a Buy rating on the stock and has a price target of $75.00. In the last 30 days, insiders have sold $4.28M worth of SNAP shares. Over the last 3 months, the insider sentiment on Snap has been negative based on 154 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Stem Inc is down -5.68% in midday trading to $21.92. Shares opened today at $23.24. The company has a 52-week low of $9.60 and a 52-week high of $51.49. In the last 30 days, insiders purchased $500K worth of STEM shares. Over the last 3 months, the insider sentiment on Stem Inc has been positive based on 4 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>